Barbara Gayle Duncan Insider Trading $JNCE Jounce Therapeutics, Inc.
Get free email notifications about insider trading for Barbara Gayle Duncan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Barbara Gayle Duncan. Barbara Gayle Duncan is Director in IMMUNOMEDICS INC ($IMMU) and Director in Innoviva, Inc. ($THRX) and CEO in Euthymics Bioscience Inc ($DOVP) and Director in Euthymics Bioscience Inc ($DOVP) and President and CFO in Euthymics Bioscience Inc ($DOVP) and Director in MEDGENICS, INC. ($MDGN) and Chief Accounting Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Chief Financial Officer in INTERCEPT PHARMACEUTICALS INC ($ICPT) and Director in Atea Pharmaceuticals, Inc. ($AVIR) and Director in Adaptimmune Therapeutics PLC ($ADAP) and Director in Ovid Therapeutics Inc. ($OVID) and Director in Jounce Therapeutics, Inc. ($JNCE) and Director in Fusion Pharmaceuticals Inc. ($FUSN).
Barbara Gayle Duncan in Jounce Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Barbara Gayle Duncan: Director
Holdings: 10,000 shares
Current Value: $173,000
Latest Transaction: Sep 16 2020
$JNCE Market Capitalization: $140.99M
$JNCE Previous Close: $17.30
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Barbara Gayle Duncan in Jounce Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADAP, GNMX, AVIR, DOVP, FUSN, IMMU, THRX, ICPT, JNCE, OVID
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 10,000 | 42,100 | 34,271 | |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 10.50 | 5,000 | 52,500 | 0 | 5 K to 0 (-100.00 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 9.50 | 5,000 | 47,500 | 5,000 | 10 K to 5 K (-50.00 %) |
| Sep 16 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Buy | M | 4.21 | 10,000 | 42,100 | 10,000 | 0 to 10 K |
| Jun 29 2020 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 7.58 | 13,550 | 102,709 | 13,550 | |
| Jun 13 2019 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 4.46 | 15,700 | 70,022 | 15,700 | |
| Jun 21 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | A | 7.92 | 13,550 | 107,316 | 13,550 | |
| Mar 19 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 2,000 | 8,420 | 44,271 | |
| Mar 19 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 28.11 | 2,000 | 56,220 | 0 | 2 K to 0 (-100.00 %) |
| Mar 19 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Buy | M | 4.21 | 2,000 | 8,420 | 2,000 | 0 to 2 K |
| Jan 29 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Option Exercise | M | 4.21 | 4,000 | 16,840 | 46,271 | |
| Jan 29 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Sell | S | 25.00 | 4,000 | 100,000 | 0 | 4 K to 0 (-100.00 %) |
| Jan 29 2018 | JNCE | Jounce Therapeutic ... | Duncan Barbara Gayle | Director | Buy | M | 4.21 | 4,000 | 16,840 | 4,000 | 0 to 4 K |
Page: 1